Take Home messages
• Increasing number of patients presenting for ophthalmic surgery are using oral anti-coagulant and anti-platelet therapy.
• The current practice of discontinuing these drugs pre-operatively due to a presumed increased risk of bleeding may not be evidence-based and could pose a significant risk to the patient's health.
• Current evidence supports the continued use of aspirin and with some exceptions, warfarin in the peri-operative period.
• The risk of thrombosis-related complications on disruption of anticoagulation may be higher than the risk of significant bleeding by continuing its use for most types of ophthalmic surgery. 
Introduction
Increasing number of patients presenting for ophthalmic surgery are using oral anticoagulant and anti-platelet therapy. 1 Common medical conditions, such as atrial fibrillation and valvular heart disease, require the use of anticoagulants (e.g. warfarin), whilst antiplatelet therapy is used in high risk populations to reduce vascular events. [2] [3] For example, there are one million people in America who are receiving warfarin, making it the 46 th most commonly prescribed drug in USA in 1993. 4 As patients over the age of 65 years are twice as likely to have some form of surgery as compared to those under that age the true importance of managing peri-operative antithrombotic therapy becomes clear. These drugs are routinely discontinued preoperatively due to a perceived increased risk of severe bleeding intra and postoperatively, a practice which is generally not based on published evidence and the potential risks to the patient may be poorly understood (Table 1) . Nonetheless, the risk of peri-operative bleeding in patients on anti-coagulants is dependant on multiple factors including the patient's age, other systemic diseases (cancer), the type of surgery as well as the INR. [5] [6] [7] The underlying clinical state, the type of surgery and the phenomenon of rebound hypercoagulability on interruption of warfarin contributes to the risk of thrombosis-related complications.
The aim of this overview is to provide a semi-systematic review of the current published evidence on the peri-operative management of anti-coagulant and anti-platelet therapy.
In particular, we will review the risk of significant bleeding in patients on anti-coagulant than others. We will also assess the risks of thrombosis-related complications associated with short-term modification of these drugs and stratify the risk on the basis of underlying systemic disease. Management of the surgical field in ophthalmic patients on anti-coagulants will be summarized.
Methods used in undertaking this overview, as well as a brief overview of the indications for anti-thrombotic therapy [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] are provided as web-only supplementary material.
Altering anti-thrombotic therapy and the risk of thrombotic complications
The risks of thrombotic complications on one hand and bleeding on the other are dependent on multiple factors, including the type of anti-thrombotic therapy, the type and duration of surgery and rebound hypercoagulability that may be associated with stopping warfarin.
Aspirin users may be placed in two broad overlapping groups: those with significant cardiovascular risk factors where aspirin plays a significant cardioprotective and antithrombotic role, and those taking aspirin to keep the circulation "healthy". There is no published evidence to suggest that aspirin use in the latter group is beneficial. In the former group, in addition to the cardio-protective effect, aspirin reduces the risk of stroke by an average of 22% 2, 21 . Of note, current guidelines recommended dual antiplatelet therapy after coronary stenting especially with drug eluting stents, as early antiplatelet discontinuation may increase the risk of stent thrombosis An overview of studies examining the effect of altering antithrombotic therapy and the risk of thrombotic complications suggests a greater risk for patients with mitral valve disease, combined mitral and aortic prosthetic valves and atrial fibrillation. The exact thrombotic risk is dependent on multiple factors including the underlying systemic condition requiring anti-coagulation, duration of disruption and the use of bridging therapy (Table 3) . [28] [29] [30] [31] [32] All these studies (either retrospective or prospective) have One study of patients undergoing cataract surgery found a greater incidence of subconjunctival hemorrhage in patients who were receiving either clopidogrel or warfarin compared to aspirin or no antithrombotic drugs, although there were no sight-threatening bleeding complications 40 .
Vitreoretinal surgery
Vitreoretinal surgery, though more invasive than cataract surgery, also appears to be safe in patients taking aspirin. For example, Narendran and Williamson 41 did not find an increased rate of bleeding complications in patients taking aspirin; however, only 7 patients in the study were taking warfarin, making it difficult to draw any firm conclusions from the higher bleeding rate in this sub-group. Fu at al. 42 
Glaucoma surgery
Trabeculectomy also appears to be safe in patients taking aspirin. In a retrospective study, Cobb et al. 44 reported that patients on aspirin had a postoperative hyphaema rate which was twofold compared to non-aspirin users, but there was no significant difference in surgical outcome when comparing intraocular pressures (IOP) at 2 years; however, 
Lacrimal surgery
Lacrimal surgery can be associated with blood loss, sometimes significant 45, 46 . In endonasal lacrimal surgery, visualisation is essential, and even a little blood loss will affect outcomes. Good hemostasis is therefore essential not only per-operatively, but also to prevent bleeding in the immediate postoperative period. Poor visibility during the operation correlates with poor outcomes.
Oculoplastic, Oro-facial & cutaneous surgery
Oro-facial and cutaneous surgery, including general plastic surgery and dermatologic procedures (eg. Moh's surgery) are broadly similar to oculoplastic and adnexal surgery, and evidence from these specialties are relevant to ophthalmologists.
Only one study investigating oculoplastic surgery in anti-coagulated patients was identified. 47 The authors concluded that the incidence of serious haemorrhagic complications was low.
Cutaneous surgery generally appears safe in anti-coagulated patients. 48 There is broad consensus that oral anticoagulants do not significantly increase the risk of bleeding and that stopping anticoagulant therapy does not offer significant benefits. [49] [50] [51] [52] The rate of Major thrombotic episodes including pulmonary embolism and thrombosis of prosthetic valve have also been reported when anticoagulant therapy was withheld prior to surgery. 55 Finally, a recent meta-analysis of complications attributed to anticoagulation in patients following cutaneous surgery reported that patients taking warfarin were nearly seven times as likely to have a moderate-to-severe complication whereas patients taking aspirin were more than two-fold (but not statistically significant) to have a moderate-tosevere complication compared to controls 56 .
Oral and dental surgery
There is evidence that oral and dental surgery is safely carried out in chronically anticoagulated patients. A prospective randomised study comparing bleeding complications in patients continued on warfarin to those that had warfarin reduced or warfarin added found no statistically significant difference in the rate of bleeding complications. 57 Another randomised controlled trial 58 of 109 patients, comparing the discontinuation of warfarin two days pre-operatively with continued anti-coagulation did not find a Topical hemostatic agents like platelet rich fibrin gel could be used in patients at a higher risk of bleeding. 60 Five trials (a total of 553 patients) were included in a recent meta-analysis that evaluated the effect of continuing warfarin therapy on the bleeding risk of patients undergoing elective dental surgery 61 . Perioperative continuation of warfarin with patients' usual dose was not associated with an increased risk for clinically significant non major bleeding or an increased risk for minor bleeding compared with interrupting warfarin therapy (either partial or complete). The preparations may be autologous, homologous and derived from pooled donors or bovine sources. To prepare the autologous gel, the patient needs to come to the hospital a few days before the procedure and give about 100-300ml of blood which is then processed to recover platelet rich fibrin glue and thrombin. 73 When this gel is applied to the operative field, the platelets come in contact with thrombin/calcium it results in their activation and coagulum formation. The platelets interdigitate with the fibrin web and develop an adhesive haemostatic layer. Platelet activation also releases highly active vasoconstrictors, including serotonin, thromboxane and platelet derived growth factor (PDGF). In addition to haemostasis, it also promotes wound healing and has "tissue glue"
properties. 73, 74 Commercially available topical agents tend to be more effective as they contain much higher concentrations of clotting factors. 75 The homologous products are screened for all currently known infectious agents but concerns remain. Bovine products like FlowSeal Matrix™ are another alternative. They are derived from closed herds that are screened for all known infections including prion diseases but the possibility of (rare) allergic reactions must be kept in mind.
A systemic review of randomised controlled trials of fibrin sealants by Carless et al 76 suggests that these agents reduce the rate of blood loss as well as reducing the need for transfusion. A multi-centre study comparing the efficacy of fibrin sealant with conventional topical haemostatic agents in emergency re-sternotomy and redo cardiac surgery found these agents to control bleeding within five minutes of application in 92.6% of patients compared to 12.4% in the conventional group. 78 A recent randomised controlled trial found it to be safe and effective in controlling post-operative bleeding following adenoid surgery in children. 79 It does not appear to alter wound healing or flap survival in clinical studies but delayed mucosal healing and increased scarring was reported in one animal study. 80, 81 Though there is no published evidence of the use of these topical products in orbital surgery, a recent study of trans-sphenoidal surgery found Flowseal to be effective in controlling severe bleeding where standard methods had failed. 82 Tisseal™, another topical agent is effective as hemostatic agent and tissue glue. 83 One of the major benefits of this product is the ability to vary the clotting rate by changing the dilution of the thrombin in the preparation.
Haemostatic sponges have been around for a long time and are used either alone or after soaking them in thrombin. 84 They work primarily by activating platelets and providing scaffolding for clot formation. 85 Bone wax is a useful and cheap alternative for controlling moderate bleeding from bone.
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Conclusions
Even with the limited quality and quantity of evidence we are able to draw certain conclusions from the available data (Table 4) . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 While aspirin does not appear to be associated with an increased risk of significant bleeding in patients undergoing any type of ophthalmic surgery or infiltration of local anesthesia, no evidence of excessive thromboembolism on its discontinuation was identified. In procedures where oozing at the operative site may be detrimental to surgical outcome, aspirin may be discontinued in the peri-operative period in patients without significant cardio-vascular risk factors. The risk of significant bleeding in patients using warfarin and undergoing ophthalmic surgery appears to be relatively low when the INR is within the therapeutic range, whilst the probability of thromboembolism on its interruption appears to be much higher. Peri-operative modification of warfarin needs to be done cautiously and in close discussion with a cardiologist and/or clinical haematologist. Reducing the warfarin dose pre-operatively to bring down the INR to the lower limit of the therapeutic range is a safer alternative to disrupting it and exposing the patient to a risk of thromboembolism. There is also insufficient evidence to make precise recommendations about the newer anti-platelet drugs like clopidogrel and prasugrel. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 27. Rowbotham BJ, Whitaker AN, Harrison J, Murtaugh P, Reasbeck P, Bowie EJ. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w O n l y 32 Evidence based recommendations for peri-operative management of warfarin and aspirin.
Measurement of crosslinked fibrin derivatives in patients undergoing abdominal
Aspirin or warfarin should not be discontinued prior to periocular infiltration of local anesthetic (sub-tenon, peri-bulbar or retro-bulbar).
In the presence of vasculopathic risk factors, aspirin should not be stopped prior to any type of ophthalmic surgery.
Cataract surgery can be safely carried out in patients taking aspirin or warfarin.
*With the exception of vitreo-retinal surgery, warfarin should be continued in patients undergoing ophthalmic surgery as the risk of thrombophilia is higher than the risk of significant bleeding.
Peri-operative modification of anti-coagulants should only be carried out after advice from a cardiologist/ clinical hematologist.
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